Pre-Clinical Research

Psilocybin and Psilocin

Using fungi to extract the active tryptamines from the biomass to yield psilocybin and psilocin in the form of pure crystalline isolate, salts, tinctures and high bioavailable water-soluble liquids and dry powders. Nirvana plans to sell these products to other researchers under a Dealer’s License from Health Canada.

The extraction of psilocybin and other structurally similar substituted tryptamines from fungi followed by their conversion to the metabolic prodrug 4-POpsilocin. This process is a novel method to yield a new  psychoactive substituted tryptamine that has a highly desirable effect.  The onset is fairly rapid and the duration is roughly 4 hours.

This novel compound will be ideal for use in a clinical setting due to its short duration and the lack of any apparent body load that’s often associated with psilocybin. We are currently in the finalization phase of the patent process and acquiring this compound for exclusive use in the clinical pharmaceutical market.

Nirvana is also in the process of creating a fully synthetic route to yield psilocybin and psilocin from 4-hydroxytryptophan in large batch quantities. This synthetic psilocybin will be a standardized USP grade  pharmaceutical.

Iboga and Ibogaine (Tabernanthe Iboga)

Ibogaine is a naturally occurring alkaloid that has been reported to decrease various adverse phenotypes associated with exposure to drugs of abuse and alcohol in human and rodent models. We believe that this compound could be valuable as a clinical  medication when used cautiously. We have developed an exclusive multi-phase process to extract  ibogaine alkaloids from the root bark of the tabernanthe iboga shrub. This extraction process yields both a broad spectrum total alkaloid  freebase powder and a pure hydrochloride salt. We are currently in the process of developing a cost effective batch  scale synthesis of noribogaine and its 13-hydroxy variant. Noribogaine (12-hydroxyibogamine) is a metabolite of ibogaine.

In addition to novel formulation development, there is also the opportunity for IP development for the mechanized manufacturing of these new medicines that incorporate our Licensed delivery systems and mechanisms.